Sonoma Pharmaceuticals (SNOA) Depreciation & Amortization (CF) (2010 - 2026)

Sonoma Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $33000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 6.45% year-over-year to $33000.0 in Q1 2026; TTM through Mar 2026 was $139000.0, a 0.72% increase from a year earlier, with the FY2026 full-year figure at $139000.0, up 0.72% from the prior year.
• Depreciation & Amortization (CF) fell to $33000.0 in Q1 2026 per SNOA's latest filing, from $34000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $49000.0 in Q1 2022 and bottomed at $28000.0 in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $35000.0 (2024), against an average of $36882.4.
• Across the five-year window, Depreciation & Amortization (CF) tumbled 46.15% in 2022 and jumped 60.71% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $32000.0 in 2022, then jumped by 40.62% to $45000.0 in 2023, then retreated by 26.67% to $33000.0 in 2024, then advanced by 3.03% to $34000.0 in 2025, then dropped by 2.94% to $33000.0 in 2026.
• Per Business Quant, the three latest SNOA Depreciation & Amortization (CF) figures stand at $33000.0 (Q1 2026), $34000.0 (Q4 2025), and $36000.0 (Q3 2025).